Anaplastic thyroid cancer. Issue 5 (October 2015)

• Record Type: Journal Article
• Authors: Ranganath, Rohit; Shah, Manish A.; Shah, Ashok R.
• Is Part Of: Current opinion in endocrinology, diabetes and obesity. Volume 22:Issue 5(2015:Oct.)
• Publication Date: 2015-10
• Subjects: Endocrinology -- Periodicals; Diabetes -- Periodicals; Obesity -- Periodicals; Diabetes Mellitus -- Periodicals; Endocrine System Diseases -- Periodicals; Endocrine Glands -- Periodicals; Obesity -- Periodicals; Endocrinologie -- Périodiques; Diabète -- Périodiques; Obésité -- Périodiques; Diabetes; Endocrinology; Obesity; Periodicals; 616.4
• DOI: 10.1097/MED.0000000000000189
• Languages: English
• ISSNs: 1752-296X

Abstract

<abstract> <title> <x xml:space="preserve">Abstract</x> </title> <sec> <title>Purpose of review</title> <p>Anaplastic thyroid cancer (ATC) is a rare malignancy of the thyroid with a high mortality rate. Conventional therapy has not been effective. Several biological agents are being investigated. The purpose of the review is to highlight the current standards for treatment and review new targets for treating ATC.</p> </sec> <sec> <title>Recent findings</title> <p>Retrospective studies have led to formulation of guidelines for management, including those by the American Thyroid Association. An expansion in the understanding of the genetic mutations has led to several newer biological agents being tested to treat ATC. Aurora kinase inhibitors, PPAR γ agonists, and vascular targeting agents are some of the latest therapeutic agents that have shown promise and could become standard of therapy with further supporting research.</p> </sec> <sec> <title>Summary</title> <p>Further well coordinated preclinical and clinical research is needed to support the emerging treatments for ATC.</p> </sec> </abstract>